Ambien (Zolpidem tartrate) Central nervous system agent Sedatives and hypnotics, nonbarbiturate Zolpidem tartrate is indicated for the short-term treatment of insomnia. Hypnotics should generally be limited to 7 to 10 days of use; and re-evaluation of the patient is recommended if they are to be taken for more than 2 to 3 weeks. Adults: 10 mg/day immediately before bedtime. Maximum 10 mg/day. Children less that 18 years of age: Not recommended. Category B Dizziness, drowsiness, "drugged feeling," headache, confusion, and hiccups. Do not use for benzodiazepine or ethanol withdrawal. Pregnancy Risk Categories defined: A: Studies in pregnant women failed to show a risk to the fetus in the first trimester - with no evidence of risk in the later trimesters. B: Animals studies indicate no adverse effect to the fetus, but there are no adequate, clinical studies in pregnant women. C: Animal studies have shown an adverse effect on the fetus, but there are no adequate, clinical studies in humans. Despite potential risks, the drug may be useful in pregnant women. D: There is evidence of risk to the human fetus, but the potential benefits of use in pregnant women may be acceptable, despite potential risks. X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any potential benefit from using the drug in pregnant women, regardless of trimester. NR: Not rated (i.e., no information available at this time as to the potential risks or benefits).